CLINUVEL has developed new biocompatible liquid drug formulations with sustained-release capabilities for peptides and melanocortins. These formulations aim to predict drug release kinetics and allow for flexible dosing by adjusting injection volumes. The preclinical program is expected to be completed by the second half of 2026. The Chief Scientific Officer, Dr. Dennis Wright, expressed confidence in the progress made after a decade of in-house research. If successful, these new depot formulations could serve as a platform for delivering various peptides, benefiting patients of all ages. CLINUVEL is a global specialty pharmaceutical group focused on developing innovative treatments for various disorders.

Read more at GlobeNewswire: CLINUVEL to advance novel pharmaceutical formulations in